BrianA Posted August 11, 2022 Report Share Posted August 11, 2022 everything in the news is "Major" now apparently 😀  "In small, early-stage studies, Pfizer and Valneva reported no safety problems and a good immune response. The newest study will test if the vaccine, called VLA15, really protects and is safe. The companies aim to recruit at least 6,000 people in Lyme-prone areas including the Northeast U.S. plus Finland, Germany, the Netherlands, Poland and Sweden.  ...  Volunteers can be as young as 5 and should be at high risk because they spend a lot of time in tick-infested areas, such as hikers, campers and hunters"  https://apnews.com/article/science-health-ticks-73fab8e29f3e2243c2db5bc33b3265e1 Quote Link to comment Share on other sites More sharing options...
IgorF Posted August 11, 2022 Report Share Posted August 11, 2022 Hm, according to the article in Plotkin's Vaccines (7th ed. 2018) there were already studies with OpsA in 90ies and despite the expected "mechanics" of this approach worked ok these vaccines were rather "1st generation" and they were probably expected to be administered with 3 initial shots and a buster every 2 years. Also US strains and EU strains (3 active) were different thus no cross-protection observed. In EU 2 perspective studies also created something and then closed the projects (no idea why). On the other hand, Borelia with its unique abilities to move against the blood flow, cross the bbb, hide from the immunity mechanisms and so on is a really tough beast to beat, so if the newer vaccs will be not much better than the old studied this could be still a good news. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.